EU and US could reach trade deal this weekend - Reuters
Oriola-KD Oyj B reported a mixed performance for Q4 2024, with organic net sales growth of 3% and a significant 30% increase in adjusted EBIT. Despite these positive financial results, the stock declined by 3.13% in pre-market trading, reflecting investor concerns over market share and consumer confidence issues. According to InvestingPro analysis, the company appears undervalued based on its Fair Value calculations, with the stock showing relatively low price volatility (Beta: 0.62). The company’s strategic initiatives and operational updates were highlighted, but market reactions suggest cautious investor sentiment.
Key Takeaways
- Oriola-KD Oyj B achieved a 3% organic net sales growth in Q4 2024.
- Adjusted EBIT increased by 30%, reaching €21.6 million.
- The company’s stock price fell by 3.13% in pre-market trading.
- Market share in Sweden slightly declined, impacting investor sentiment.
- Strategic acquisitions and innovations in data-driven services were emphasized.
Company Performance
Oriola-KD Oyj B demonstrated resilience in Q4 2024 with a 3% organic growth in net sales, reaching €1 billion. The company’s adjusted EBIT saw a substantial increase of 30%, reflecting effective cost management and strategic focus on high-value pharmaceutical services. InvestingPro data reveals the company maintains a strong dividend profile with a 6.85% yield and has raised its dividend for three consecutive years. The slight market share decline in Sweden and ongoing weak consumer confidence in both Sweden and Finland posed challenges. For deeper insights into Oriola-KD’s financial health and growth prospects, investors can access comprehensive analysis through InvestingPro’s detailed research reports.
Financial Highlights
- Revenue: €1 billion, 3% organic growth
- Adjusted EBIT: €21.6 million, 30% increase
- Distribution segment: 81% of net sales, 67% of adjusted EBIT
- Wholesale segment: 19% of sales, 33% of adjusted EBIT
Market Reaction
The stock price of Oriola-KD Oyj B decreased by 3.13% in pre-market trading, dropping from a last close value of 1.022. This decline suggests investor caution, potentially due to the company’s market share issues in Sweden and broader economic factors affecting consumer confidence.
Outlook & Guidance
Looking ahead, Oriola-KD expects adjusted EBITDA to increase in 2025, with a focus on achieving market-standard performance for Kronan’s Apotheque by 2027. The company is committed to continuing its strategic execution and has proposed a dividend of $0.07 per share. InvestingPro analysis shows the company operates with a moderate level of debt (Debt/Equity: 0.51) and maintains a significant free cash flow yield, though it currently faces profitability challenges with negative earnings in the last twelve months.
Executive Commentary
"We had a good financial performance with sales growth and improved profitability," stated CEO Katerina Gabrielsen, highlighting the company’s positive results. CFO Mats Danielson added, "We expect the adjusted EBITDA to increase from 2024," signaling confidence in future growth. Gabrielsen also emphasized the company’s commitment to enhancing customer centricity.
Risks and Challenges
- Weak consumer confidence in Finland and Sweden could impact sales.
- Market share decline in Sweden, particularly in weight loss products.
- Potential effects of prescription medicine wholesale price reduction in Finland.
- Ongoing cost inflation, despite a slowing trend.
- Execution risks associated with the ERP project in Sweden.
Q&A
During the earnings call, analysts inquired about the one-time costs in the joint venture, which amounted to €6.7 million, primarily related to ERP efforts. Questions also focused on the Danish acquisition strategy and the expected profitability of Kronan’s Apotheque.
The company’s performance in Q4 2024 highlights both its strategic strengths and the challenges it faces in maintaining market share and navigating economic uncertainties.
Full transcript - Oriola-KD Oyj B (OKDBV) Q4 2024:
Tuas Denus Stordiam, Investor Relations, Aureola: Good morning, everyone, and a warm welcome to Aureola’s Q4 and Full Year Results Webcast. My name is Tuas Denus Stordiam, and I’m from Aureola’s Investor Relations. With me today, I have our CEO, Katerina Gabrielsen and CFO, Mats Danielson. After the presentation, we will open up for your questions. But I would like to remind you that we will focus on the questions relating to Orellas business and financial performance and take questions about Kronesaapotec only within the limited scope that we can comment on.
You can send in your questions already during the presentation using the chat function in the webcast player. I would also like to remind you that we are recording this webcast and the on demand version will be available on our website at a later point today. And now if we go to the next slide, here we have the customary disclaimer that we all should be aware of. And now without further ado, I would like to hand over to Katharina. Please go ahead.
Katerina Gabrielsen, CEO, Aureola: Thank you, Tuwa. And also welcome on my behalf. This is the agenda for today’s webcast. First, we will look at the 24 highlights for full year. We will look at the operating environments, the segments and then also go through the financial numbers in a little bit more detail.
And like Tuohaz said, we will then end this session with a Q and A. If we then look at the full year 2024, I’m really happy to see that the strategy implementation that we have done during 2024 have enhanced the financial performance that we have done made a result of today. The net sales has been growing and it has been growing with 3% in organic growth, landing on billion. The adjusted EBIT was growing 30% from million to million and without SvensDos Sweden, we are landing on €21,600,000 What we can see is that the sales growth has been improving and also the profitability has improved and that is supported by both the distribution segment and wholesale segment. We can see that we have good progress with our strategy and we have strengthened the customer centricity.
And this means that we have been working closer to the customer that means that we have then expanded the businesses together with our customers and we can also look forward to continue to do that. In the wholesale business, we have worked very much of building the foundation during the year. We have also said that before. And that means that we have now also taken the next step to continue the journey that we have in the strategy and start to then expand the wholesale business, both in the assortment business and in the advisory side. In the advisory side, we have introduced the data driven services, which means that we have then utilized more data and also technology, including AI to introduce new services for the pharmaceutical companies.
We announced in the end of last year a new operating model and that is to accelerate the strategy execution that we have then started during last year. We have during now first quarter had more commercial focus in the management team, and that means that we have two new members from January 1. That’s Sato Nillen and Katja Lundel, who is then responsible for the two commercial two units, Sato for products and services and Katja for advisory services. In February, also Thomas Tilikainen started as supply chain manager or director, and we have also then yesterday announced that we have an EVP sales starting April 1 and his name is Stig Tornel. The ERP project in Sweden has gone according to plan and the first deployment in Sweden are approaching quite fast.
In the joint venture company, Kronan’s Apotheque, we can see that the focus has been during the year on integrating the two companies and developing the network of nearly 500 pharmacies that we have. We are not satisfied with how Crohnase Apotheque has been performing and we are expecting that Crohnase Apotheque should deliver on market standard in 2027. The e commerce though in Crohnase Apotheque was growing with double digits and that’s good since we can see that you are following then what’s happening in the Swedish market in e commerce. We have also announced the dividend proposal from the Board. The Board of Directors has proposed the AGM that the dividend of $0.07 should be paid for 2024.
The record dates will be 04/04/2025 and the payment date will be the April 15. I also want to remind you about our dividend policy That is that our aim is to pay out an increasing annual dividend of two third of net profit. And of course, what we now then do here is not fully in line with the dividend policy, but we can see that our cash flow and free and also networking capital is supporting this dividend payout. Then going to the operating environment. Overall, the operating environment has been stabilizing during the year.
We can see that the consumer confidence was weak in both Finland and Sweden and we can see that it’s continuing to be weak. The cost inflation during the year has been slowing down and that means that we have more visibility to both energy prices and also fuel prices. That is a big cost for us in our businesses. Availability of pharmaceuticals is something that you can see quite much in the media and there is challenges and it has been during the whole 2024. There has been a similar kind of challenges in 2024 that was also part of 2023.
And for the future, I can also see that it will continue, unfortunately. But we can’t really see that it’s some change in this one. The value of the pharmaceutical distribution market has continued a steady growth driven by a good demand from high value pharmaceuticals. And with high value pharmaceuticals, we can, for example, see a lot of cold chain products coming into the market and also more specialized products that is not done in the generic segments in the same way as it has been before. In 2024, the pharmaceutical distribution market was growing with in Sweden with 7% and in Finland with 5%.
Then looking at each segments. In the distribution segments, we then have the pharmaceuticals that we’re distributing to pharmacies and other customers in both Sweden and Finland. The net sales was growing 16% to €362,000,000 The organic growth was growing only 2% since the market volumes are then changing and we also have a change in Aureola’s consignment to inventory stock that we announced already in quarter three. The market growth was most like there in the quarter, but we can see significant fluctuations of the volumes, especially between November and December. We have unfortunately had very much volumes and unfortunately the same because we had much volumes in December in the December, where we also have a lot of red days that the Christmas is there.
And that means that the volumes that we get in this part of December is quite costly for us. Even though we had this, the profitability improved in distribution segment by 22% and adjusted EBIT was reaching €5,900,000 The net sales was growing and we also had lower freight costs year on year. But like I said, we had higher OpEx in December. For the market share, we can see that we had stable market share in Finland and some decline in Sweden. And the main part why do we have decline in Sweden is the same as we said last time we were standing here.
There was like especially in Sweden focus on weight loss products and that is some part of this value parts medicines. In 2024, we have a strategic focus area in distribution segments as well as in wholesale segments about being closer to the customer to enhance the customer centricity and really listen to the customer being there. And this has also given us a structured approach and increasing dialogue with the customers, which has meant that we have no retention no retention in the strategic accounts and we also have new customers onboarding now in the quarter four of twenty twenty five. Then going to the wholesale segments. And in wholesale segments, we have the advisory services as well as the assortment business.
The net sales was growing 5% in this segment and the growth in Finland was supported by a wider offering and also new sales channels. In Sweden, we have both consignment stock and our own assortment and especially the own assortment that we have in Sweden was growing during the quarter. The profitability improved by 10% with adjusted EBIT landing on EUR 2,000,000. The wholesale segment is really important for us in the strategy execution and it’s a long term strategic goal to grow the wholesale business, both advisory side and the assortment side. In 2024, we have worked very much on developing the capabilities and expanding our offering And that is, of course, because we want them to have the growth coming now in 2025 and so on.
I’m happy to say that we have in quarter four a strong double digit growth in the key sales channels in the wholesale segment. And also in advisory services, we can see that we have gained traction of the recently launched data driven services that is done very much a tech part and also AI part where we use the data that we collect in the company. We have talked a lot about the Svens doors during the last year and also before that. We are now approaching a final decision in Svens doors And that is expected to come in March 2025. And as soon as we know something more, we will, of course, announce that.
With that, I’ll leave you with Mats to go a little bit deeper on the financial figures.
Mats Danielson, CFO, Aureola: Thank you, Katharina, and good morning from my side also. Now we can go a bit further into the 2024 under financials. And we’ll start with the quarter four. We had net sales organic growth of 3%. As Katharina also said, we had during last year a large customer moving from consignment to inventory, which means that the distribution is having a 16% increase.
On the wholesale, especially in the quarter four, Finland had a good growth there. So on total, it was a 14% improvement. Looking at the adjusted EBIT for the quarter going from 5,400,000.0 to 6,400,000.0, we had an improvement of 1,000,000 in the distribution segment, mostly related to margin increase and lower freight costs. And there were some offsets by higher costs, especially in December due to the Red Days and Christmas and so on. So it was a bit more cost than it would have normally been.
If we look at the wholesale improvement, it’s mostly related to the increase in sales. If we look at the comparison quarter four excluding Svensk Doos, we actually have in 2023, there was a more of a technical correction for the full year related to Svenskdus, which mean that there was a positive impact on quarter four. And in real numbers, also excluding Svensklos, the profitability adjusted EBIT would have increased if that would have not been done if it would have been done in a correct way. That’s the right direction. Invoicing, if we look at the quarter, we had a bit of a lower invoicing on the quarter compared to 2% in the quarter and 5% year to date.
That has to do with the November invoicing, which was a bit of a disappointment and lower than we expected, but we caught up with that to be partly in December. Looking at net sales, there is the effect of the customer moving to inventory. So we see that the numbers, so the percentages are quite high. If we then look at the adjusted EBIT on the full year, we have a 5,000,000 increase in adjusted EBIT. Of that, 3,000,000 is related to Svenske Doos, and which had a negative result last year.
And the 2,000,000 improvement is related to margin increase, lower freight cost and then offset by some increase in cost in the operations and that mostly has to do with quarter four and the December effect there also. Good to note also that we have the we have now treated according to what we said in the last quarter. We are now treating the ERP cost mostly as a cost, not as an investment. And we had 5,900,000.0 booked as adjusting items for the ERP. And we know that there will be now during the coming years 2025, ’20 ’20 ’6 and some in 2027 related to the new ERP.
If we look at the distribution segment, we see the increase in net sales related again to the customer moving from to inventory. The organic growth was 3%. Adjusted EBIT improving year to date, 4,500,000.0. And here we can also see that the Svenske Doos, the impact is 3,000,000 and so the real improvement is 1,500,000.0, again related to margin increase and freight cost, lower freight cost and offset by some cost increases. We also see that the distribution segment has 81% of the company’s net sales and 67% of the adjusted EBIT.
Wholesale segment important part of our strategy. Here we can see that the wholesale segment, if we look at the quarter, 5% increase and 3% increase on the full year. As said, we had a good quarter in Finland adding to the good development. And if we look at the adjusted EBIT, we can see the of course, the effect of that good quarter that we had in Finland positively. And we have but we have also to remember that we have the clinical trials affecting positively on the wholesale segment.
We have had quite a lot of extra cost and employed personnel to support the wholesale segment during the year according to our strategy. Share of debt sales 19%, share of adjusted EBIT is 33%. Then if you look at the all the way down to the net profit, we can see starting from EBITDA, we have a bit of a lower EBITDA than last year. That’s related to the adjusting items that were much higher this year. We have 8,100,000.0 in adjusting items, mostly related or a big part related to the ERP project.
Then we had in the depreciations, we also had a small 1,900,000.0 that was an impairment of cost that we had in the as investments in 2023 that we wrote down in 2024 according to the handling of the treatment of the ERP cost. EBIT is 13.6. And then we see also the now the impact of the JV minus 24.8%, landing on a net profit at the same level as last year. And then we have to remember that last year we had impairment on the dose business of SEK21.4 million. So we are at the same level as last year.
We had a positive operating cash flow from operating activities, SEK38.7 million starting from EBITDA, SEK27.2 million. Percent. We had a positive change in working capital. This is an initiative that we are also working with now to look at the working capital and the cash volatility. So we will focus on put an effort on that to stabilize that.
Then we have repaid loans and we have utilized less commercial papers and prepayments from pharmacies and we are landing at the ending cash at SEK113.5 billion. And then we can look at the net debt, so it’s minus SEK37 million compared to minus 21,000,000 last year at the same time. On the right, you can also see how the debt situation is developing. We have repaid during last year repaid loans, 28,000,000. We have less commercial papers and some other lines and the interest bearing debt has gone down by 41,000,000, 40 2 million.
We have had a good cash flow, gearing is minus 28,000,000 and equity ratio has gone down now during to 15% and that is of course also related to the effect from the JV and the Kvaerner Zapotec, but also from the impact of the adjusting items that have been growing since last year. Krunas Apotheque, we had the impairment. The adjusted EBIT for the quarter was at the same level as last year. But if we look at the full year, it has been worse than last year. And in December, we announced the impairment that was done in Krones (ETR:KRNG) and affected us affect our numbers also.
Outlook, we have decided to move to comment on the adjusted EBITDA instead of adjusted EBIT that we have previously done. We think that that gives a better picture of the performance of the company. It will give a better comparability compared to previous years due to the fact that we are handling, for example, the ERP investments now in a different way than we have previously done. So we feel that this is a better way of doing it and we expect the adjusted EBITDA to increase from 2024.
Katerina Gabrielsen, CEO, Aureola: And then to wrap this up, you can stay here, Mats, if you want to. I can stay here. Yes. The key takeaways that we want you to remember is then that we we think that we had a good financial performance with sales growth and improved profitability that when you then see the guidance for 2025, we can see that we are expecting that to continue. And there are certain different things that we then would like to highlight, but especially then the new operating model that should then enhance the customer focus and drive growth.
And we have seen that it started already ’24, but it will then continue also ’25. And of course, also then the full strategy execution that we have continue to work on that and also see that the numbers will come with these achievements. So with these highlights, I don’t know if there is some questions to us.
Tuas Denus Stordiam, Investor Relations, Aureola: Thank you, Katharina and Mats for your presentations. We have a couple of questions from the chat, and they are mainly related to KRONA Zapotec. But I will take those because I believe we can still comment on these ones. So, Oriola has reported EUR 6,700,000.0 onetime costs in JV based on integration. What kind of costs are these?
Katerina Gabrielsen, CEO, Aureola: I don’t know if we should open up it too much, but of course, something is like ERP costs since we know that we have a huge ERP project ongoing in Cronas. So we’ll say main costs is from that one, as Matt also already have talked a little bit about.
Tuas Denus Stordiam, Investor Relations, Aureola: Good. Thank you. And then relating to the pharmacy business as a whole and the comment that we have added about benchmark level by 2027. So what is normal profitable level in pharmacy business in Sweden, which is expected to reach by 2027?
Katerina Gabrielsen, CEO, Aureola: What we are saying here is that we expect the Kvaerner’s business to be somewhere between what Apotekt AB and Apotekt Jattat has. And I’m not commenting as actually that level because, of course, that’s also changing. But we would like or like we think that this company can be on the same level as these two companies. All right.
Tuas Denus Stordiam, Investor Relations, Aureola: Thank you. And then there is a question relating to the wholesale in Finland or the prescription medicines in Finland. So there was a 1.5% reduction in wholesale prices for most of the prescription medicines in Finland since March 1. Does this have a direct impact on your invoicing in Finland?
Katerina Gabrielsen, CEO, Aureola: From 2024, you mean, or 2025?
Tuas Denus Stordiam, Investor Relations, Aureola: The question says first March twenty twenty five.
Katerina Gabrielsen, CEO, Aureola: Okay. Of course, there will be some effects on that one, but I don’t see that it should be like an alarming one because we can also see that the market is growing. So in that aspect, I’m not seeing that it should drag down the business.
Tuas Denus Stordiam, Investor Relations, Aureola: Okay. And then yes. And then still on the KRONA Zapotecxo, do you expect to reach normal level profitability level in JV steadily quarter by quarter by 2027? Or will there be any bigger steps within next two years?
Katerina Gabrielsen, CEO, Aureola: That’s hard to say. We’re not normally commenting like that one. But what we expect, of course, is that we should improve from the basic figure or the figures that we have now because we can’t continue on this level.
Tuas Denus Stordiam, Investor Relations, Aureola: All right. Good. And then there is another question. So here is about Finnish wholesale. So you mentioned that the profitability in Finnish wholesale was slightly positive.
Does this mean that it has been loss making in previous quarters?
Katerina Gabrielsen, CEO, Aureola: No. But we can see that in quarter four, we can see that we have some effects that we have then started to build during the year. So it’s not loss making, but of course it’s like I always want the businesses to be better and this is one comment for that one. We had good growth in the wholesale business in Finland, especially in the channels that is really important for us and that is, of course, good for the future also.
Mats Danielson, CFO, Aureola: And a good result also.
Katerina Gabrielsen, CEO, Aureola: That’s true. I’m baking it together much.
Tuas Denus Stordiam, Investor Relations, Aureola: Okay, good. And then there is a question relating to the new customers that we have commented on. So you have new customers onboarding at the start of 2025. Can you talk more about this? What is the size of these customers?
And will that become visible in Q1?
Katerina Gabrielsen, CEO, Aureola: Yes. We are onboarding now during quarter one. So of course, you will see some part of it in quarter one, but not the full effect until later. It’s a customer that is done it’s visible or like has business in both Sweden and Finland and also in all the like both in pharmaceutical side and also advisory side. So that gives an effect that should be visible in the numbers.
Tuas Denus Stordiam, Investor Relations, Aureola: All right. And then there’s a question relating to dose dispensing business. So is it fair to expect the result from the dose dispensing business to be fairly in line with 2023 or maybe 2024?
Katerina Gabrielsen, CEO, Aureola: Depends, of course, also now we are, of course, in the dose dispensing. Sweden are waiting now for the results. And that is, of course, something that I think both you and we are eagerly waiting for to know what we should do with this business for the future. If you should also say that the Swedish dose dispensing business during 2024 has been running on without depreciations and extra costs. So it’s more like a maintenance part that we do.
So depending on, of course, what the outcome will be and how we then continue with that, that will affect, of course, the numbers. But I hope we can announce this as soon as possible.
Tuas Denus Stordiam, Investor Relations, Aureola: Good. So that and Iris just commented that she meant 2024, that it will it be on the same level as in 2024. Okay. I think let’s see if we have any more questions. I think we need to wait a little bit because there is the lag between the live webcast and how the questions pop up here.
But we can also ask a question about that we didn’t mention about the acquisition that we made in Denmark. So would you like to comment
Katerina Gabrielsen, CEO, Aureola: a little bit about that? Yes. I can comment on that one. A couple of weeks ago, we announced that we are then buying MedInfo. And MedInfo is a small acquisition that were made in Denmark.
And they are mainly working for medical information and patient support programs, which is an important part of the advisory services that we do. And they have been like a subcontractor to OREOLA before and works mainly for Denmark and Norway. And when we look at the advisory business, it’s important to be in the whole Nordic because there is local language required and a lot of the pharmaceutical companies is then expecting us to cover the whole Nordic or like these four countries at least. And this was something we can do then. So we are like fulfilling this customer requirement and looking forward then to expand that business.
Tuas Denus Stordiam, Investor Relations, Aureola: Great. Thank you. So one more question relating to the ERP investment and financial impact going forward. Would you like to comment a little bit on that one?
Mats Danielson, CFO, Aureola: Yes. Like we said, we have in the plan to invest up to million in the new ERP and that will be mostly taken as a cost, not as an investment. That will go on now for up to 27%. So it’s three more years where we book this cost. 10% is roughly that we calculated that has will be as an investment.
So it will be hitting our net result as an adjusting item during the coming years.
Tuas Denus Stordiam, Investor Relations, Aureola: All right. Good. Thank you. So we don’t have any other questions on the chat at the moment. So I think we can conclude the presentation for today.
I would like to just remind about our next event. So during next week, we will publish our annual report. And then the annual general meeting will be held on the April 2. And the Q1 report is going to be published on the April 29. But that’s all for us today.
Thank you, everyone, for joining our webcast. And if you have any questions or want to follow-up with any topics, please don’t hesitate to reach out to us. Thank you.
Katerina Gabrielsen, CEO, Aureola: Thank you.
Mats Danielson, CFO, Aureola: Thank you.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.